Here's Why You Should Add Immunovant (IMVT) to Your Portfolio [Yahoo! Finance]
Immunovant, Inc. (IMVT)
Company Research
Source: Yahoo! Finance
The company currently has no marketed products in its commercial portfolio. Immunovant's clinical-stage pipeline comprises its lead product candidate, batoclimab (formerly known as IMVT-1401), and a new candidate, IMVT-1402, which are being developed as a subcutaneous injection for the treatment of IgG-mediated autoimmune diseases. Let's delve deeper to discuss four reasons why adding IMVT stock to your portfolio may prove beneficial in 2024. Batoclimab, a Promising Candidate: Immunovant is developing its lead candidate, batoclimab, for several diseases with an initial focus on the treatment of myasthenia gravis (MG), an autoimmune disease associated with muscle weakness, and thyroid eye disease (TED), an autoimmune inflammatory disorder that affects the muscles and other tissues around the eyes, which can threaten sight. Top-line data from the pivotal study evaluating batoclimab for the treatment of MG is expected in the second half of 2024. Initial data readouts from two add
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Batoclimab (IMVT-1401) for Graves' Ophthalmopathy Drug Landscape Report 2024: Market Size, Forecast, and Emerging Insights for 7MM 2019-2032 [Yahoo! Finance]Yahoo! Finance
- Should You Hold Immunovant (IMVT)? [Yahoo! Finance]Yahoo! Finance
- What Makes Immunovant (IMVT) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Immunovant, Inc. (NASDAQ: IMVT) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $50.00 price target on the stock.MarketBeat
IMVT
Earnings
- 2/12/24 - Beat
IMVT
Sec Filings
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- IMVT's page on the SEC website